Responsive Playbooks and the RIGL Inflection
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) through an AI-driven lens, highlighting a near-term positive sentiment amidst a mid-term weak bias and long-term strength. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and provides multi-timeframe signal analysis and risk-reward ratios. The analysis suggests an exceptional 77.6:1 risk-reward setup targeting a 22.2% gain.
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
Rigel Pharmaceuticals (RIGL) stock has risen 59% in the past year, significantly outperforming the industry, largely driven by strong sales of its drug Tavalisse. Preliminary fourth-quarter and full-year 2025 results show robust revenue growth, and the company projects continued momentum and profitability in 2026 despite competitive pressures from larger drugmakers. Analysts suggest holding the stock due to its growth potential and positive outlook.
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
Shares of Rigel Pharmaceuticals (RIGL) have surged 59% in the past year, significantly outperforming the industry, sector, and S&P 500. This growth is primarily driven by the strong performance of its drug Tavalisse, which accounted for approximately two-thirds of total revenues in Q4 2025, alongside contributions from oncology assets. Despite competitive risks and trading at a slight premium, the company's positive financial guidance for 2026 and increasing analyst estimates suggest continued growth potential, leading to a Zacks Rank #3 (Hold) recommendation.
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?
Rigel Pharmaceuticals (RIGL) stock has significantly outperformed its industry, sector, and the S&P 500 over the past year, driven by strong performance from its marketed product Tavalisse and growing contributions from its oncology drugs. The company reported robust preliminary financial results for Q4 and full-year 2025 and projects continued growth in 2026, aiming for positive net income. Despite competitive threats from larger pharmaceutical companies, Rigel's pipeline and positive analyst outlook suggest growth potential, leading to a Zacks Rank #3 (Hold) recommendation.
Reasons to Consider Rigel Pharmaceuticals (RIGL) as a Strong Momentum Stock: Is It Time to Buy?
Rigel Pharmaceuticals (RIGL) is highlighted as a strong momentum stock with a Zacks Rank of #1 (Strong Buy) and a Momentum Style Score of B, demonstrating significant price increases over the last year. Analyst ratings indicate a "Moderate Buy" consensus with price targets ranging from $38 to $71, reflecting confidence in its commercial execution and promising pipeline. Recent corporate developments include new board appointments, projected 2025 revenues of $275 to $290 million, and strategic partnerships, all contributing to a positive growth outlook for the biotechnology company.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages
Rigel Pharmaceuticals (NASDAQ:RIGL) has received a consensus "Hold" recommendation from seven brokerage firms, with an average 12-month price target of $43.20. The company recently surpassed its quarterly earnings and revenue estimates, reporting strong financial metrics such as a 40.17% net margin and 204.70% ROE. Institutional investors have also shown increased interest in RIGL, with several hedge funds growing their positions in the stock.
Rigel Pharmaceuticals Charts Course Toward Profitability
Rigel Pharmaceuticals is aiming for profitability in 2026, driven by strong preliminary Q4 2025 revenues of $69.8 million and a 2026 revenue forecast of $275 to $290 million. The company has also appointed Michael P. Miller to its Board to enhance commercial capabilities and is progressing with its R289 drug candidate for myelodysplastic syndromes, with initial Phase 1b data expected by year-end 2026. Investors are awaiting audited 2025 full-year results on March 3 for further assessment.
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $42
Piper Sandler analyst Allison Bratzel has reiterated a "Hold" rating for Rigel Pharmaceuticals (RIGL.US) and significantly increased the target price from $23 to $42. This adjustment comes from an analyst with a reported 64.5% success rate and an average return of 54.3% over the past year, according to TipRanks data. The information is provided for informational purposes only and is not investment advice.
Understanding the Setup: (RIGL) and Scalable Risk
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), indicating weak near and mid-term sentiment despite a positive long-term outlook. It highlights a unique 79.6:1 risk-reward setup targeting a 23.1% gain with minimal risk, and outlines three AI-generated trading strategies for different risk profiles. The analysis provides specific entry, target, and stop-loss levels based on multi-timeframe signal analysis.
Rigel Pharmaceuticals Appoints Michael P. Miller to Board
Rigel Pharmaceuticals has appointed Michael P. Miller to its board of directors, effective February 1, 2026. Miller will serve on the Compensation Committee and receive standard non-employee director compensation, including stock options. Analysts maintain a Buy rating on Rigel stock with a $57.00 price target.
Rigel Pharmaceuticals Appoints Michael P. Miller to Board
Rigel Pharmaceuticals has appointed Michael P. Miller to its board of directors and Compensation Committee, effective February 1, 2026. Miller will receive standard director compensation, including cash retainers and an initial option grant. TipRanks' AI Analyst, Spark, rates RIGL as "Outperform" due to strong financial performance and attractive valuation, despite some pipeline risks.
Rigel Appoints Michael P. Miller to the Board of Directors
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced the appointment of Michael P. Miller to its Board of Directors. Mr. Miller brings over four decades of experience in commercial and leadership roles within the biotechnology and pharmaceutical industries. His expertise is expected to provide valuable insights as Rigel executes its strategic plan, particularly in growing its current product portfolio and evaluating in-licensing opportunities.
Veteran biotech commercial leader Michael P. Miller joins Rigel board
Rigel Pharmaceuticals (Nasdaq: RIGL) has appointed Michael P. Miller to its Board of Directors, effective February 3, 2026. Miller brings over four decades of commercial and leadership experience in the biotechnology and pharmaceutical industries, including executive roles at Jazz Pharmaceuticals and Genentech. His expertise is expected to support Rigel's strategic goals of growing its marketed medicines and exploring in-licensing opportunities to expand its hematologic and oncology portfolio.
Rigel Appoints Michael P. Miller to the Board of Directors
Rigel Pharmaceuticals, Inc. has announced the appointment of Michael P. Miller to its Board of Directors. Mr. Miller brings over four decades of commercial and leadership experience in the biotechnology and pharmaceutical industries. His expertise will be valuable as Rigel executes its strategic plan to grow its portfolio and explore in-licensing opportunities.
Rigel Pharmaceuticals Appoints New Board Member
Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors, leveraging his 40 years of commercial and leadership experience in biotechnology and pharmaceuticals. Miller's expertise is expected to help Rigel expand its drug portfolio and explore new opportunities, supporting its growth as a profitable company with a strong development pipeline. He expressed commitment to improving patient lives, particularly those with hematologic disorders and cancer.
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
The article compares two rare disease biotech stocks, FOLD (Amicus Therapeutics) and RIGL (Rigel Pharmaceuticals), evaluating their fundamentals, product portfolios, and market positions. It concludes that Amicus Therapeutics, despite being acquired by BioMarin, presents a more visible growth story due to the strong performance of its marketed products and the event-driven opportunity of the acquisition, making it a better pick over Rigel Pharmaceuticals which faces significant competitive and regulatory risks.
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
H.C. Wainwright analyst Joseph Pantginis has reaffirmed a Buy rating for Rigel Pharmaceuticals (RIGL.US) and maintained a target price of $57. This recommendation comes from an analyst with a 46.5% success rate and an average return of 11.8% over the past year, according to TipRanks data. The analysis provided is for informational purposes and not an investment recommendation.
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Strong Sell" Rating by Zacks Research
Zacks Research has downgraded Rigel Pharmaceuticals (NASDAQ:RIGL) from a "strong-buy" to a "strong-sell" rating, despite the company recently beating earnings estimates. The consensus rating from other analysts currently stands at "Hold" with a price target of $43.20. Rigel Pharmaceuticals reported strong quarterly earnings of $1.46 EPS against an estimate of $0.93, along with revenues of $69.46 million, and currently has a low P/E ratio of 6.10.
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A GARP Stock with Affordable Growth and Strong Fundamentals
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) is identified as a "Growth at a Reasonable Price" (GARP) stock due to its affordable valuation, strong growth prospects, and solid financial fundamentals. The company boasts a low P/E ratio, impressive recent EPS and income growth, and a positive shift to profitability, backed by a healthy financial status. The article suggests that despite the biotech industry's inherent risks, RIGL's current market valuation may not fully reflect its potential for expansion, making it an attractive option for investors seeking growth without excessive risk.
Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance
Rigel Pharmaceuticals (RIGL) has garnered attention after initiating a new Phase 1b/2 trial for REZLIDHIA in acute myeloid leukemia and providing 2026 revenue guidance of US$275 million to US$290 million. Despite recent positive developments, the share price has seen a 7-day return of 8.23% and a 30-day return of 10.63%, contrasting with longer-term momentum. Analysts currently view RIGL as 26.8% undervalued, with a fair value estimate of US$51.20 against a current price of US$37.48.
Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance
Rigel Pharmaceuticals (RIGL) has garnered attention due to a new Phase 1b/2 trial for REZLIDHIA in acute myeloid leukemia and a 2026 revenue guidance of US$275 million to US$290 million. Despite recent share price cooling, the company shows strong one-year and three-year returns. Simply Wall St's analysis suggests RIGL is undervalued at US$37.48 compared to a fair value estimate of US$51.20, presenting a potential investment opportunity.
Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) released its preliminary Q4 2025 results and 2026 outlook, anticipating Q4 revenue around $69.8 million and full-year 2025 revenue of $294.3 million. Management projects 2026 total revenue between $275 million and $290 million. H.C. Wainwright reiterated a Buy rating with a $57 price target following the announcement.
Precision Trading with Rigel Pharmaceuticals Inc. (RIGL) Risk Zones
This article analyzes Rigel Pharmaceuticals Inc. (RIGL) using AI models to provide trading strategies and risk zones. It identifies weak near and mid-term sentiment potentially challenging a positive long-term outlook, highlighting an exceptional short setup for risk-reward. The analysis offers specific entry, target, and stop-loss points for position trading, momentum breakout, and risk hedging strategies across different time horizons.
HC Wainwright Has Negative Forecast for RIGL FY2026 Earnings
HC Wainwright has revised its FY2026 earnings per share forecast for Rigel Pharmaceuticals (NASDAQ: RIGL) down to $3.14 from $5.19, while reaffirming a "Buy" rating and a $57 price target. The firm also provided EPS estimates for FY2027 ($3.92) and FY2028 ($4.73). This comes despite Rigel previously reporting strong quarterly results, beating EPS and revenue expectations.
Rigel Pharmaceuticals price target raised to $71 from $69 at Citi
Citi has increased its price target for Rigel Pharmaceuticals (RIGL) from $69 to $71, while maintaining a Buy rating on the shares. This adjustment reflects the company's better-than-expected fourth-quarter revenue figures. The updated model suggests a positive outlook for Rigel Pharmaceuticals' financial performance.
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
H.C. Wainwright has reiterated its Buy rating for Rigel Pharmaceuticals (RIGL.US), maintaining a target price of $57. Analyst Joseph Pantginis has a 46.5% success rate and an average return of 11.8% over the past year. The report highlights that TipRanks, an independent third party, provides this analytical data for informational purposes only and not as investment advice.
Rigel Pharmaceuticals (RIGL) Is Down 7.7% After Issuing Detailed 2026 Revenue Mix Guidance – Has The Bull Case Changed?
Rigel Pharmaceuticals recently issued 2026 revenue guidance, projecting total revenue between US$275 million and US$290 million, with a split between net product sales and contract revenue. This guidance marks a shift from their prior 2025 outlook, showing increased reliance on contract income. The article suggests investors should closely examine this revenue mix and its implications for Rigel's future growth, especially as the Medicare Part D tailwind normalizes.
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. announced inducement grants consisting of 24,775 stock options and 16,555 restricted stock units to 11 non-executive employees. These grants were made under the company's Inducement Plan, approved by the Compensation Committee, and are compliant with NASDAQ Listing Rule 5635(c)(4) as an inducement for employment. The awards vest over four years with a one-year cliff.
Rigel Pharmaceuticals, Inc. announces inducement grants under Nasdaq Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company is a biotechnology firm focused on developing novel therapies for hematologic disorders and cancer, with key products like TAVALISSE and REZLIDHIA. This announcement follows several recent company updates, including earnings reports and data presentations from ongoing studies.
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. announced inducement grants under NASDAQ Listing Rule 5635(c)(4). The company granted 24,775 stock options and 16,555 restricted stock units to 11 non-executive employees, vesting over four years with a one-year cliff. These grants are intended to incentivize new employees joining Rigel.
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?
Rigel Pharmaceuticals (NASDAQ: RIGL) had US$59.7m in debt at the end of September 2025, but also US$137.1m in cash, resulting in a net cash position of US$77.4m. The company's liquid assets significantly exceed its total liabilities, suggesting it can manage its debt safely. Furthermore, Rigel's impressive EBIT growth of 1,152% last year and solid free cash flow generation indicate a strong ability to handle its financial obligations.
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?
Rigel Pharmaceuticals (NASDAQ:RIGL) has a net cash position of US$77.4m, with US$137.1m in cash offsetting US$59.7m in debt as of September 2025. The company also boasts more liquid assets than total liabilities and showed impressive EBIT growth of 1,152% last year. These factors suggest that Rigel Pharmaceuticals is not using too much debt and can safely manage its current financial obligations.
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio
Onco360, a leading independent specialty pharmacy, has partnered with Rigel Pharmaceuticals to become a national specialty pharmacy provider for three of Rigel's therapies: TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib), and REZLIDHIA® (olutasidenib). This partnership expands Onco360's portfolio of limited distribution therapies, focusing on oncology, rare, and complex diseases, with a commitment to personalized service and clinical expertise.
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio
Onco360, a leading independent specialty pharmacy, has announced a partnership with Rigel Pharmaceuticals to include TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib), and REZLIDHIA® (olutasidenib) in its limited distribution portfolio. This collaboration expands Onco360's offerings in oncology, rare, and complex disease treatments. The company aims to provide personalized service, clinical expertise, and compassionate support to patients and caregivers.
SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Rigel Pharmaceuticals Leads With Fostamatinib and Hutchmed's Sovleplenib Emerges as Late-Stage Breakthrough Candidate for ITP - ResearchAndMarkets.com
The SYK Inhibitors market is experiencing rapid growth, driven by the increasing recognition of SYK's role in immune response and inflammation. Rigel Pharmaceuticals with fostamatinib and Hutchmed with Sovleplenib are leading players, with the market expected to expand significantly by 2030 due to new drugs, indications, and combinations with other immunotherapies. The report highlights the current clinical landscape, key companies, and future opportunities in treating autoimmune diseases, hematological conditions, and cancer.
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio
Onco360, a leading independent specialty pharmacy, has partnered with Rigel Pharmaceuticals to become a limited distribution specialty pharmacy partner for three of Rigel's therapies: TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib), and REZLIDHIA® (olutasidenib). This collaboration aims to expand Onco360's portfolio of limited distribution therapies and provide personalized service, clinical expertise, and compassionate support to patients and caregivers. Onco360 focuses on oncology, rare, and complex diseases, emphasizing improved access and adherence to treatments.
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its President and CEO, Raul Rodriguez, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 14, 2026, at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA. A live webcast and archived recording will be available on the company's investor relations website.
RIGL: Future Returns Will Reflect Stronger Execution And Raised 2025 Sales Guidance
Analysts have increased Rigel Pharmaceuticals' fair value estimate to US$51.20, up from US$49.60, driven by strong Q3 product sales, a raised 2025 net product sales guidance of US$225m to US$230m, and improved profit margin assumptions. The company also updated its overall 2025 revenue guidance to US$285m to US$290m, including contract revenues, and expects to achieve positive net income while advancing clinical development programs. Rigel provided updates on its clinical pipeline, including data for R289 in myelodysplastic syndrome and REZLIDHIA in acute myeloid leukemia.
Pacer Advisors Inc. Buys New Position in Rigel Pharmaceuticals, Inc. $RIGL
Pacer Advisors Inc. has acquired a new position in Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), purchasing 77,480 shares valued at approximately $2.195 million during the third quarter of 2025. This move gives Pacer Advisors approximately 0.43% ownership, contributing to the 66.23% institutional ownership of the biotechnology company. Analyst sentiment is mixed, with a consensus "Hold" rating and a target price of $43.20, although recent reports from Jefferies and HC Wainwright have been more bullish.
Range Financial Group LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL
Range Financial Group LLC has made a new investment in Rigel Pharmaceuticals, Inc., purchasing 45,377 shares valued at approximately $1.29 million during the third quarter. This new position represents about 0.25% of Rigel Pharmaceuticals. The biotechnology company recently reported strong quarterly earnings, topping analyst estimates with an EPS of $1.46 and revenue of $69.46 million, leading to analyst upgrades and a consensus target price of $43.20.
Inspire Investing LLC Makes New $859,000 Investment in Rigel Pharmaceuticals, Inc. $RIGL
Inspire Investing LLC has acquired a new stake of 30,322 shares in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) valued at approximately $859,000. This investment highlights Rigel's recent strong quarterly earnings, where the company surpassed EPS and revenue estimates, and its attractive P/E ratio of 7.13. Analyst ratings are mixed, with both "Buy" and "Hold" recommendations, and a consensus price target of $43.20.
Assenagon Asset Management S.A. Decreases Holdings in Rigel Pharmaceuticals, Inc. $RIGL
Assenagon Asset Management S.A. significantly reduced its stake in Rigel Pharmaceuticals Inc. ($RIGL) by 91.9% in the third quarter, while other institutional investors made various adjustments to their holdings. Rigel Pharmaceuticals reported strong quarterly earnings, beating analyst expectations for both EPS and revenue, showcasing a healthy net margin and return on equity. The company’s stock currently has a "Hold" consensus rating from analysts with an average target price of $43.20, and it trades at a P/E ratio of 7.24 with a market cap of $810.58 million.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) appears to be undervalued by approximately 23% based on a discounted cash flow (DCF) model, with a projected fair value of US$58.35 compared to its current share price of US$44.64. The analysis involved a 2-stage growth model to estimate future cash flows and considered factors such as the company's strong earnings growth, healthy balance sheet, and positive future earnings forecasts. However, the article emphasizes that valuation is not an exact science and encourages investors to conduct their own due diligence, considering various risks and assumptions.
opportunities
Wall Street Zen upgraded Rigel Pharmaceuticals (NASDAQ:RIGL) to a "Buy" rating, joining other recent positive analyst actions, though the consensus remains a "Hold." The company reported strong quarterly earnings, beating expectations for both EPS and revenue, demonstrating a high net margin and return on equity. Rigel Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing small molecule therapeutics for immune, hematologic, and oncologic diseases.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Analysts
Rigel Pharmaceuticals (NASDAQ:RIGL) has received a consensus "Hold" rating from analysts, with seven firms contributing to the recommendation (four hold, three buy) and an average 12-month target price of $43.20. The company reported strong Q3 earnings, exceeding EPS and revenue estimates, but analysts project a lower EPS for the current year. Institutional investors hold a significant portion of the stock, which is currently trading near $41.77.
Behavioral Patterns of RIGL and Institutional Flows
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), identifying a weak near and mid-term sentiment that contrasts with a strong long-term outlook. It highlights a mid-channel oscillation pattern and presents an exceptional 83.3:1 risk-reward setup. The analysis also details three AI-generated institutional trading strategies tailored for different risk profiles.
Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m
Over the last year, Rigel Pharmaceuticals' insiders sold US$424k worth of stock at an average price of US$21.39 per share. Following a 11% stock price drop and a US$97m market value decline, these insider sales appear to have been a prudent move. While no insiders bought shares in the last year, the company still maintains 1.4% insider ownership, indicating some alignment between management and shareholders.
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Hold" Rating by Wall Street Zen
Rigel Pharmaceuticals (NASDAQ:RIGL) has been downgraded to a "Hold" rating by Wall Street Zen, aligning with a mixed consensus from analysts that includes three Buy ratings and four Hold ratings, resulting in an average target price of $43.20. The company recently reported strong quarterly earnings, beating analyst expectations with an EPS of $1.46 and revenue of $69.46 million. Despite the downgrade, institutional ownership remains high at 66.23%, with several major investors increasing their stakes.
Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m
Over the past year, Rigel Pharmaceuticals insiders sold US$424k worth of stock at an average price of US$21.39, which proved to be a good move as the company's market value recently declined by US$97m. The President, Raul Rodriguez, made the largest sale, offloading US$200k worth of shares, representing only 5.9% of his holdings. Despite the insider selling, Rigel Pharmaceuticals insiders still own 1.4% of the company, valued at approximately US$10m.
Rigel Pharmaceuticals Inc Presents Updated Data from Phase 1b Study on R289
Rigel Pharmaceuticals Inc. announced promising results from its Phase 1b study of R289 for lower-risk MDS patients, showing preliminary efficacy and good tolerability. The drug achieved RBC transfusion independence in 33% of transfusion-dependent patients and sustained cytokine inhibition levels. The company anticipates selecting a recommended Phase 2 dose by mid-2026, with R289 already holding Orphan Drug and Fast Track designations from the FDA.
